These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33529886)

  • 1. Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia.
    MacDonald TM; Tong S; Myers J; Cannon P; Nguyen TV; Keenan E; Murray E; Harper A; Pritchard N; Hannan NJ; Dane KM; Middleton AL; Kyritsis VP; Walker SP; Kaitu'u-Lino TJ
    Placenta; 2021 Feb; 105():32-40. PubMed ID: 33529886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker.
    Cruickshank T; MacDonald TM; Walker SP; Keenan E; Dane K; Middleton A; Kyritsis V; Myers J; Cluver C; Hastie R; Bergman L; Garcha D; Cannon P; Murray E; Nguyen TV; Hiscock R; Pritchard N; Hannan NJ; Tong S; Kaitu'u-Lino TJ
    J Am Heart Assoc; 2021 Aug; 10(16):e020302. PubMed ID: 34387117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Death associated protein kinase 1 (DAPK-1) is increased in preeclampsia.
    Yung C; MacDonald TM; Walker SP; Cannon P; Harper A; Pritchard N; Hannan NJ; Kaitu'u-Lino TJ; Tong S
    Placenta; 2019 Dec; 88():1-7. PubMed ID: 31563554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort.
    Villa PM; Hämäläinen E; Mäki A; Räikkönen K; Pesonen AK; Taipale P; Kajantie E; Laivuori H
    BMC Pregnancy Childbirth; 2013 May; 13():110. PubMed ID: 23663420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Activin A is elevated at 36 weeks' gestation preceding a diagnosis of preeclampsia.
    Wong GP; Andres F; Walker SP; MacDonald TM; Cannon P; Nguyen TV; Keenan E; Hannan NJ; Tong S; Kaitu'u-Lino TJ
    Pregnancy Hypertens; 2022 Mar; 27():23-26. PubMed ID: 34844073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
    J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women.
    Forest JC; Thériault S; Massé J; Bujold E; Giguère Y
    Clin Chem Lab Med; 2014 Aug; 52(8):1169-78. PubMed ID: 24535301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased placental expression of Placental Protein 5 (PP5) / Tissue Factor Pathway Inhibitor-2 (TFPI-2) in women with preeclampsia and HELLP syndrome: Relevance to impaired trophoblast invasion?
    Karaszi K; Szabo S; Juhasz K; Kiraly P; Kocsis-Deak B; Hargitai B; Krenacs T; Hupuczi P; Erez O; Papp Z; Kovalszky I; Than NG
    Placenta; 2019 Jan; 76():30-39. PubMed ID: 30803712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor.
    Espinoza J; Romero R; Nien JK; Gomez R; Kusanovic JP; Gonçalves LF; Medina L; Edwin S; Hassan S; Carstens M; Gonzalez R
    Am J Obstet Gynecol; 2007 Apr; 196(4):326.e1-13. PubMed ID: 17403407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia].
    Gao J; Shen J; Jiang Y; Zhou X; Qi H; Liu X; Liu J; Yang J; Bian X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jan; 49(1):22-5. PubMed ID: 24694913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes.
    Holmes VA; Young IS; Patterson CC; Maresh MJ; Pearson DW; Walker JD; McCance DR;
    Diabetes Care; 2013 Nov; 36(11):3671-7. PubMed ID: 23920083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
    Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
    Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early diagnosis of preeclampsia using placental growth factor: An operational pilot study in Maputo, Mozambique.
    Manriquez Rocha B; Mbofana F; Loquiha O; Mudenyanga C; Ukah UV; Magee LA; von Dadelszen P
    Pregnancy Hypertens; 2018 Jan; 11():26-31. PubMed ID: 29523269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic indicators of severe disease in late preterm pre-eclampsia to guide decision making on timing of delivery: The PEACOCK study.
    Duhig KE; Seed PT; Placzek A; Sparkes J; Hendy E; Gill C; Brockbank A; Shennan AH; Thangaratinam S; Chappell LC
    Pregnancy Hypertens; 2021 Jun; 24():90-95. PubMed ID: 33770588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes of plasma and placental tissue factor pathway inhibitor-2 in women with preeclampsia and normal pregnancy.
    Xiong Y; Zhou Q; Jiang F; Zhou S; Lou Y; Guo Q; Liang W; Kong D; Ma D; Li X
    Thromb Res; 2010 Jun; 125(6):e317-22. PubMed ID: 20347477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating angiogenic factors and the risk of preeclampsia.
    Levine RJ; Maynard SE; Qian C; Lim KH; England LJ; Yu KF; Schisterman EF; Thadhani R; Sachs BP; Epstein FH; Sibai BM; Sukhatme VP; Karumanchi SA
    N Engl J Med; 2004 Feb; 350(7):672-83. PubMed ID: 14764923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes.
    Salahuddin S; Wenger JB; Zhang D; Thadhani R; Karumanchi SA; Rana S
    Hypertens Pregnancy; 2016 Aug; 35(3):330-45. PubMed ID: 27028795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
    MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
    BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preeclampsia: the role of tissue factor and tissue factor pathway inhibitor.
    Godoi LC; Gomes KB; Alpoim PN; Carvalho Md; Lwaleed BA; Sant'Ana Dusse LM
    J Thromb Thrombolysis; 2012 Jul; 34(1):1-6. PubMed ID: 22461171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.